Conclusions
pSS
The primary endpoint of this study, the proportion of patients showing an improvement in ESSDAI score (≥3 points from baseline to week 12), was not met. RO5459072 was generally well-tolerated in patients with pSS. Further work is needed to clarify the role of cathepsin S and MHC-II-mediated immune stimulation in pSS.